Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Tolerability Trial of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor Hematopoietic Stem Cell Transplant

NCT01012492 is registered in ClinicalTrials.gov with Boston Children's Hospital as lead sponsor.

NCT NCT01012492
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01012492 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Tolerability Trial of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor Hematopoietic Stem Cell Transplant
Lead sponsor
Boston Children's Hospital
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2009
Completion date
January 31, 2013
Enrollment
11 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

all, aml, biphenotypic leukemia, mds associated with isolated del (5q), myelodysplastic syndrome, unclassified, ref. cytopenia w multilineage dysplasia & ringed sideroblasts, refractory anemia, refractory anemia with excess blasts-1 (5-10% blasts), refractory anemia with excess blasts-2 (10-20% blasts), refractory anemia with ringed sideroblasts, refractory cytopenia with multilineage dysplasia, undifferentiated leukemia